Sorsby fundus dystrophy (SFD) is a macular degeneration caused by mutations in TIMP3, the majority of which introduce a novel cysteine. However, the exact molecular mechanisms underlying SFD remain unknown. We aimed to provide novel insights into the functional consequences 
INTRODUCTION
Sorsby fundus dystrophy (SFD; MIM# 136900) is a rare, autosomal dominant retinal dystrophy in which patients experience a sudden loss of central vision related to the development of choroidal neovascularization (CNV) or macular atrophy during the fourth or fifth decade of life (Sorsby, Joll Mason, & Gardener, 1949) . The disease is characterized by thickening of the Bruch membrane, chorioretinal atrophy, and multiple drusen-like deposits throughout the entire fundus.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. These deposits are very similar to findings in early age-related macular degeneration (AMD; MIM# 603075) (Gourier & Chong, 2015) , however the diffuse Bruch membrane thickening observed in SFD is not limited to the macula as in AMD. Typical manifestations include night blindness, scotoma, and metamorphopsia with subsequent reduced central, detailed vision and color vision problems (Christensen, Brown, Cree, Ratnayaka, & Lotery, 2017) . In the more advanced stages, peripheral vision is lost with the development of widespread atrophy, with any remaining function hampered by periph-eral CNV and scarring Gliem et al., 2015) . Management of CNV in the later stages of the disease can be successful using vascular endothelial growth factor (VEGF)-inhibitors (Gourier & Chong, 2015) . SFD is a fully penetrant disease with large interfamilial and intrafamilial variability in age of onset, progression rate, and morphological features (Christensen et al., 2017; Gliem et al., 2015) .
SFD is caused by mutations in TIMP3 (MIM# 188826) , which is a member of the family of tissue inhibitor of matrix metalloproteinases (TIMPs). TIMPs are key regulators of the matrix metalloproteinases (MMPs), zinc-dependent endopeptidases that degrade the extracellular matrix (ECM) and shed cell surface molecules (Brew & Nagase, 2010; Clark, Swingler, Sampieri, & Edwards, 2008) . TIMP3 is unique among its family members as it is the only TIMP localized to the ECM (Qi & Anand-Apte, 2015; Visse & Nagase, 2003) . The protein is secreted by the retinal pigment epithelium (RPE) and deposited in the ECM of the Bruch membrane, where it regulates the thickness of the Bruch membrane by inhibiting MMPs (Weber, Vogt, Pruett, Stöhr, & Felbor, 1994) . Mutations in TIMP3 result in an increased accumulation of the TIMP3 protein and a thickening of Bruch membrane, leading to reduced permeability for trafficking metabolites and nutrients (Kamei & Hollyfield, 1999) . However, the exact molecular mechanisms underlying SFD remain unknown.
Each TIMP contains an N-and C-terminal domain, which fold into a highly conserved tertiary structure. The N-terminal domain forms a ridge that fits into the active site of the MMPs, thus inhibiting these MMPs (Li, Clarke, Barker, & McKie, 2005; Nagase, Visse, & Murphy, 2006) , whereas the C-terminal domain ascertains the interaction with the ECM and inhibits activation of pro-MMPs (Brew & Nagase, 2010; Nagase et al., 2006) . The three-lobed structure of each domain is maintained by three disulfide bonds, formed by 12 conserved cysteine residues in total (Li et al., 2005; Nagase et al., 2006) . To date, 18 distinct mutations causing SFD have been identified (Christensen et al., 2017) , the majority of which are missense mutations located in the C-terminal domain of the protein (Bakall, Sohn, Riley, Brack, & Stone, 2014; Schoenberger & Agarwal, 2013) . One mutation causes the loss of a cysteine, whereas 13 mutations result in an additional cysteine residue (Gliem et al., 2015) . Most studies hypothesize that mutant TIMP3 proteins with unpaired cysteines form abnormal disulfide-bonded dimers and aggregates that decrease the turnover of the protein in the Bruch membrane, thus leading to a disturbed homeostasis in ECM remodeling and thickening of Bruch membrane (Arris et al., 2003; Langton, Barker, & McKie, 1998; Langton, McKie, Smith, Brown, & Barker, 2005; Langton et al., 2000; Lin, Blumenkranz, Binkley, Wu, & Vollrath, 2006; Saihan et al., 2009; Soboleva, Geis, Schrewe, & Weber, 2003; Weber et al., 2002; Yeow et al., 2002) .
Despite this widely accepted hypothesis, no study already proved the existence of novel disulfide bonds, either intra-or intermolecular.
Importantly, abnormal disulfide bonding cannot be the only cause of SFD as two missense mutations do not lead to the introduction or loss of a cysteine. Controversy also exists about the dimerization capacity of the p.(Ser179Cys) TIMP3 mutant, as some show dimerization of the mutant (Langton et al., 2005) and others not (Qi et al., 2002) .
Overall, these findings underscore our current lack in understanding the pathogenetic mechanism underlying SFD.
In 2000, Assink et al. examined a large Belgian family with typical SFD. Although linkage was found with the 22q12.1-q13.2 region containing TIMP3, no TIMP3 mutation was identified (Assink et al., 2000) .
Here, it was our aim to elucidate the genetic cause of SFD in this family and two other SFD families, and functionally characterize the mutant proteins.
MATERIALS AND METHODS

Editorial policies and ethical considerations
Research protocols adhered to the tenets of the Declaration of Helsinki and were approved by the ethical committee of Ghent University (B670201733128). Patients provided written informed consent for the study.
Clinical evaluation of patients
Three seemingly unrelated families diagnosed with SFD, two Belgian and one French, were investigated. A detailed ophthalmologic examination at baseline (consultation at presentation) included assessment of Snellen best-corrected visual acuity (BCVA) and refraction, slit-lamp examination, Goldmann applanation tonometry, dilated ophthalmoscopy and extensive fundus imaging using standard color fundus photography (Topcon TRC-50EX fundus camera; Topcon Corporation, Tokyo, Japan), confocal scanning laser ophthalmoscopy with blue and near-infrared auto-fluorescence (BAF and NIR-AF), near-infrared reflectance (NIR-R) and red-free (RF) imaging (cSLO; Heidelberg Retina Angiograph HRA2; Heidelberg Engineering, Dossenheim, Germany), and spectral domain optical coherence tomography (SD-OCT, Heidelberg Spectralis OCT; Heidelberg Engineering, Dossenheim, Germany). Existing clinical records were revisited and a full medical history was obtained to provide detailed clinical data for each patient. Patients were investigated and questioned about age and mode of onset and the natural course of the disease over the years. 
Mutation analysis of TIMP3
All five TIMP3 (RefSeq NM_000362.4) coding exons and adjacent splice sites were amplified from genomic DNA by polymerase chain reaction (PCR) (Supporting Information Table S1 ). PCR products underwent Sanger sequencing using the BigDye R Terminator Cycle Sequencing kit on an ABI3730xl DNA analyzer (both Applied Biosystems).
The obtained sequences were analyzed with the SeqScape software (Applied Biosystems). All genomic positions are based on genome build GRCh37/hg19.
Haplotyping of the TIMP3 p.(Ser38Cys) mutation
The haplotype was determined based on five probands from family 1 (IV:31, IV:56, IV:59, V:30, and V:33), two siblings from family 2 (II:1 
TIMP3 expression analysis
Dermal fibroblasts derived from a skin biopsy of two patients (IV:56 according to manufacturer's instructions. cDNA was synthesized with the iScript cDNA synthesis kit (Bio-Rad Laboratories) using 500 ng of mRNA, followed by reverse-transcription quantitative PCR (RT-qPCR)
using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories). The expression level of TIMP3 was determined using intronspanning primers (primerXL (Lefever et al., 2017) ). Data analysis was done using the qBase+ software (Biogazelle) with following reference genes for normalization: HMBS, YWHAZ, and SDHA. Primer sequences are listed in Supporting Information Table S1 .
Preparation of fibroblast cells and Western blot analysis
Dermal fibroblast cultures of two patients (IV:56 and IV:59) and agematched controls were cultured as described above. Cells were seeded at 300,000 cells per well in six well plates and were grown until confluence. After 48 hr, transforming growth factor beta-1 (TGF 1, and scanned with the ChemiDoc-It R 500 Imaging System (UVP).
In blots with M-PER cell lysates, relative densities of glycosylated TIMP3 were calculated on three independent Western blots using Image J. Relative ratios of glycosylated TIMP3 were calculated to the total amount of TIMP3 present in the sample. Statistical analysis was done using an unpaired t-test. ECM extracts were made by removing dermal fibroblasts from the well by trypsinization, subsequent washing with phosphate buffered saline (PBS) and scraping of the remaining proteins in ECM buffer containing 100 mM Tris-HCl [pH 6.8], 10% glycerin, and 1% SDS (Weber et al., 2002) . SDS-PAGE and protein transfer to nitrocellulose membrane was performed as described above. Membranes were blocked for 2 hr and immunolabeled with primary antibody (AB6000, Merck Millipore, 1:2000 or MAB3318, Calbiochem, 1:1000), respectively diluted in 2% BSA or 2% membrane blocking agent in TBST for 16 hr at 4 • C. Membranes were probed with secondary antibody and developed as described above.
In vitro transcription and translation of TIMP3 protein and subsequent Western blot analysis
We constructed wild type (WT) and mutant (c.113C>G, p. (Ser38Cys) and c.536C>G, p. were grown to obtain larger quantities.
In vitro transcription and translation of generated WT and mutant expression constructs was done using the T7 TnT R Quick Coupled antibodies (AB6000, Merck Millipore, 1:2000 or MAB3318, Calbiochem, 1:1000) were used as described earlier.
Molecular modeling of TIMP3-MMP2 interaction
A homology model for full-length TIMP3 was generated using the homology modeling command in YASARA structure (version 17.8.15) using the structure of TIMP2 (PDB code: 1GXD, chain D) as a template (http://yasara.org/products.htm#structure). Homology modeling used a MAFFT alignment (Supporting Information Figure S1A ) guided by structural alignment of TIMP2 (1GXD) and the TIMP3 N-terminal domain (3CKI) (Katoh & Standley, 2013) . A model for the complex of full-length TIMP3 with pro-MMP2 was generated as above, but now using TIMP2 and pro-MMP2 as templates, as present in the 1GXD template structure (chain A and C). A model of TIMP3 with MMP2 was generated by superposing the structure of the MMP2 protease domain (PDB code: 1QIB) on the TACE protease domain in the TIMP3/TACE crystal structure (PDB code: 3CKI) using UCSF chimera matchmaker, superposing only a selection of residues around the metal binding site (Supporting Information Figure S1B ) (Pettersen et al., 2004) . After removal of the TACE structure, residues 100-121 of TIMP3 were replaced by residues of the full-length TIMP3 homology model using YASARA structure, generating a model of fulllength TIMP3 with MMP2. The model was energy minimized using the YASARA em_runclean macro.
The effect of mutations on protein structure was analyzed using the YASARA structure md_refine protocol, which combines 500 ps molecular dynamics, with energy minimization of frames taken at 25 ps intervals. The mutation was tested in the crystal structure of the TIMP3 N-terminal domain (PDB code: 3CKI, without TACE) and in the homology model of full-length TIMP3. Both WT and mutant were subjected to five different md_refine runs. The energy minimized structures with lowest energy of each simulation, and the structures after 400, 425, 450, 475, and 500 ps simulation were all compared after different structural superpositions in UCSF chimera and YASARA. Visual inspection of the superpositions revealed no reproducible visible differences between the WT and mutant models.
Prediction of the effect of the p.(Ser38Cys) mutation on protein stability
The effect of the p.(Ser38Cys) mutation on the protein stability was tested using FoldX (Guerois, Nielsen, & Serrano, 2002) , DUET (Pires, Ascher, & Blundell, 2014) , and MAESTRO (Laimer, Hofer, Fritz, Wegenkittl, & Lackner, 2015 expression constructs, used to predict the effect of the p. (Ser38Cys) mutation on disulfide bond formation. The mutations were inserted using the Q5 site-directed mutagenesis kit (New England Biolabs), and mutation-specific primers were designed with the NEBaseChanger software (New England Biolabs) (Supporting Information Table S1 ).
Mutated plasmids were transformed in One Shot TOP10 competent cells (Invitrogen, Life Technologies) and subsequently isolated with the NucleoBond Xtra Midi/Maxi kit (Macherey-Nagel). The entire TIMP3
insert was sequenced and selected plasmids were grown to obtain larger quantities. Sequencing primers can be found in Supporting Information Table S1 . In vitro transcription and translation was performed as described above.
RESULTS
Clinical evaluation of three SFD families
Supporting Information Table S3 summarizes the phenotypic data for the three families. Only one third of the patients explicitly complained about night blindness in their fifth decade. The other patients did not, although the majority of them were older than 50 years. In one patient photophobia was more important early on in the disease course.
When examined in the third decade, the fundus appearance was All patients kept an optimal best-corrected visual acuity in at least one eye until the sixth decade (with the exemption of one patient). Patients in the seventh decade or older had rapidly evolved toward legal blindness due to macular scarring and/or atrophy. However, in these older patients CNVs commenced unfortunately in a pre-anti-VEGF era and therefore rapid scarring was unavoidable (Figure 2) . Two patients continue to undergo regular intravitreal injections with anti-VEGF (offlabel bevacizumab). In one patient, this was advised despite BCVA loss and macular scarring in order to reduce peripheral CNV activity and to preserve peripheral visual function.
None of our patients had pulmonary involvement. Although, currently, no further investigations were performed to detect asymptomatic air trapping in the absence of clinical signs, symptoms, or complaints. (Figure 1a ). In addition, the mutation was identified in 13 individuals who, as far as we know, do not present with a SFD phenotype yet and are indicated with a black dot on the pedigree (Figure 1a) . Subsequently, the same N-terminal mutation was identified in two additional SFD families, family 2 and 3 (Figure 1b,c) . The mutation segregated with disease in four individuals of family 2. 
Identification
The p.(Ser38Cys) mutation is a founder mutation
The p.(Ser38Cys) mutation does not lead to the formation of higher-molecular weight proteins
To study the effect of the identified mutation on protein level, we performed extensive Western blot analyses on whole cell lysates and ECM extracts of patient and control fibroblasts using two different lysis The mutation studied here is indicated in bold. The N-and C-terminal domains are separated by a dashed line (Bakall et al., 2014; Barbazetto, Hayashi, Klais, Yannuzzi, & Allikmets, 2005; Felbor et al., 1996; Felbor, Stohr, Amann, Schonherr, & Weber, 1995; Felbor, Suvanto, Forsius, Eriksson, & Weber, 1997; Fung, Stöhr, Weber, Holz, & Yannuzzi, 2013; Gliem et al., 2015; Jacobson et al., 1995 Jacobson et al., , 2002 Langton et al., 2000; Lin et al., 2006; Saihan et al., 2009; Schoenberger & Agarwal, 2013; Tabata, Isashiki, Kamimura, Nakao, & Ohba, 1998; Weber et al., 1994) buffers, both reducing and nonreducing conditions, and three different anti-TIMP3 antibodies, each recognizing a different epitope. TIMP3
and its glycosylated form have a respective molecular weight of 25
and 27 kDa and can be seen on all blots using patient fibroblasts (Figure 5a-f) . We confirmed TIMP3 localization to the ECM, as ECM extracts show a clear enrichment in TIMP3 protein (Figure 5e ,f).
Western blot analysis was performed on whole cell lysate using Laemmli lysis buffer and two different antibodies (Calbiochem, Sigma) (Figure 5a,b) . Statements about higher-molecular weight forms Western blot analysis on in vitro transcription and translation products of wild type and mutant TIMP3 constructs using two primary TIMP3 antibodies (g: Calbiochem; h: Merck). TIMP3 and glycosylated TIMP3 have a respective molecular weight of 25 and 27 kDa. Previous hypotheses about higher-molecular weight proteins could not be confirmed, however mild hyperglycosylation was observed in patients versus controls when using M-PER lysis buffer (c,d). Abbreviations used: P = patient, C = control, ECM = extracellular matrix, TGF = transforming growth factor beta, wt = wild type TIMP3, N term = TIMP3 with N terminal mutation p.(Ser38Cys), C term = TIMP3 with C terminal mutation p.Ser179Cys, NT = no template control occurring only in patients could not be made as nonspecific bands, (Figure 5a,b) . As TIMP3 is known to localize to the ECM (Li et al., 2005) , ECM extracts were collected of patient and control fibroblasts.
Western blot analysis on these extracts was performed, using the same antibody as in Figure 5a (Calbiochem) (Figure 5e ). We cannot explain the increased intensity of glycosylated TIMP3 in P1, which was not present anymore when repeating the experiment on new ECM extracts using a third antibody (Merck) (Figure 5f ).
More interestingly, the nonspecific band at 50 kDa seen in Fig Overall, based on all antibodies that were tested in this study, we prefer the AB6000 antibody (Merck Millipore) to analyze TIMP3 proteins, as this is the most sensitive for TIMP3 and shows the least nonspecific binding.
Structural modeling of TIMP3-(pro-) MMP2 interaction
The crystal structure of the N-terminal domain of TIMP3 has been determined in complex with the TACE catalytic domain (PDB code CKI) (Wisniewska et al., 2008) . We further built molecular models of the complete TIMP3, and of complete TIMP3 with MMP2 (Figure 6a Table S4 ), which is in concordance with the Western blot results showing no difference in protein expression between wild type and mutant forms of TIMP3.
In the crystal structure and homology models, Ser38 is not close to the TIMP3 interface with TACE, MMP2 (Figure 6a ) or pro-MMP2 (Figure 6b) . However, a p.(Ser38Cys) mutation could affect the binding by long-range structural effects. We further mutated Ser38 to cysteine in the structure and homology model, followed by analyses of the mutant and WT protein using the Yasara md_refine protocol (Krieger et al., 2009 ). This protocol combines short molecular dynamics and energy minimization with the YASARA2 forcefield, and on average improves protein structure models (Krieger et al., 2009 ). This approach does not indicate any remarkable effect of the p.(Ser38Cys) mutation on the protein structure. Together, stability prediction and modeling do not provide convincing indications that a p.(Ser38Cys) mutation strongly affects stability or structure of the TIMP3 protein.
However, these approaches cannot predict the consequences of the introduction of the new cysteine on misfolding due to faulty new disulfide bridges during the folding process. For example, Ser38 is in close proximity to Cys36, which forms a disulfide bridge with Cys143 (Figure 6b) . A cysteine at position 38 may compete with this correct disulfide bridge formation and interact with Cys36 to form a novel, aberrant disulfide bond.
The p.(Ser38Cys) mutation possibly disrupts an intramolecular disulfide bond
As we hypothesize that the Cys36-Cys143 disulfide bond may be disrupted by the introduction of the p. (Ser38Cys) 
DISCUSSION
We have identified the causal mutation of SFD in three different families from Belgian or French origin. All affected individuals are heterozygous for the c.113C>G, p.(Ser38Cys) mutation in exon 1 of the TIMP3 gene, which was previously missed in family 1 due to less sensitive screening methods (Figure 1 ). This mutation has been associated with relatively late onset SFD leading to choroidal neovascularization, with or without pulmonary involvement (Meunier et al., 2016; Schoenberger & Agarwal, 2013; Warwick et al., 2015) . We confirm a later onset in the families identified here, segregating the p. secretory pathway, such as TIMP3, as they are exposed to highly oxidizing environments (Bechtel & Weerapana, 2017; Ellgaard, McCaul, Chatsisvili, & Braakman, 2016) .
So far, it is unclear how the disease develops and a mechanism explaining the pathogenicity of TIMP3 mutations is currently lacking.
A first hypothesis suggests a gain of function whereby mutant TIMP3
proteins containing an unpaired cysteine form abnormal disulfidebonded dimers and aggregates that slow down turnover in the Bruch membrane (Langton et al., 2000) . Dimerization/multimerization of the mutant protein has been shown for different C-terminal mutations (Arris et al., 2003; Christensen et al., 2017; Langton et al., 1998; Langton et al., 2005; Saihan et al., 2009; Soboleva et al., 2003; Weber et al., 2002; Yeow et al., 2002) (Supporting Information Table S5 ). However, some discrepancies remain on the ability of mutant proteins to dimerize/oligomerize, depending on the cell line or expression construct used (Langton et al., 2005) . Furthermore, this hypothesis is less likely for mutations that do not lead to the gain or loss of a cysteine (Lin et al., 2006; Saihan et al., 2009) . A second hypothesis involves reduced capacity of mutant TIMP3 to inhibit MMP activity or VEGF signaling.
Again contradictory results exist, where a retained MMP inhibitory function was shown for the majority but not all of TIMP3 mutations evaluated (Christensen et al., 2017; Langton et al., 2005; Langton et al., 2000; Qi et al., 2002; Yeow et al., 2002) ) (Supporting Information   Table S5 ).
No functional data concerning the p.(Ser38Cys) mutation are currently available. As this mutation gives rise to an unpaired cysteine, we performed extensive Western blot analyses on different sample types and using different antibodies to assess the presence of TIMP3 In a loss of function model, the mutant protein has a reduced ability to inhibit MMPs or VEGF, which would lead to ECM dysregulation and CNV (Christensen et al., 2017) . Further research is necessary to determine which model is applicable for the p.(Ser38Cys) mutation and if all SFD-variants have a shared disease mechanism.
In the current study patient-derived fibroblasts were used, similar to previous papers (Arris et al., 2003; Weber et al., 2002) . However, given the major involvement of the RPE, other cell types such as induced pluripotent stem cell (iPSC)-derived RPE from patients with SFD would be of interest in assessing the downstream effect of the altered intramolecular disulfide bonding and how this mutation affects the RPE. This cell type already showed great potency in mimicking adult human RPE and it has been shown that iPSC-RPE from patients with SFD exhibits drusen and ECM alterations (Galloway et al., 2017 ).
In conclusion, we identified a heterozygous TIMP3 founder mutation (c.113C>G, p.(Ser38Cys)) in three families with late-onset SFD.
We were not able to confirm the general hypothesis on abnormal intermolecular disulfide bonding resulting in aberrant TIMP3 protein dimerization. Instead, we propose a novel pathogenetic mechanism for this N-terminal mutation comprising the formation of a novel intramolecular disulfide bond with a potential effect on TIMP3 glycosylation.
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